Seqirus makes plans to transition to cell-based flu vaccine

Seqirus announced plans manufacture its influenza vaccine for the 2019-2020 season using an exclusively cell-based production process for the first time. Russell Basser, senior vice president of research and development at Seqirus, told Infectious Diseases in Children that several studies have demonstrated the potential benefits of cell-based influenza vaccines compared with egg-based vaccines.